Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

LONDON, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present in a fireside discussion at the BMO Prescriptions for Success Healthcare Conference, to be held 12 December 2018 in New York.

Mereo BioPharma Presentation Details

Date: Wednesday, 12 December 2018

Time: 8:20-8:40 AM ET (1:20-1.40 PM BST)

Location: Mandarin Oriental, 80 Columbus Circle, New York, NY 10023

Track & Room: South Salon 1

ABOUT MEREO

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo’s strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. In December 2018, Mereo announced the proposed combination of Mereo and OncoMed Pharmaceuticals, with the transaction expected to close in the first half of 2019. Each of Mereo’s four product candidates has previously generated positive clinical data for Mereo’s target indication or in a related indication. Since inception Mereo has commenced large, randomized, placebo-controlled Phase 2 clinical trials for all four of the product candidates:

  • BPS-804 for osteogenesis imperfecta (OI). The Company recently announced completion of enrolment with 112 adult patients in a Phase 2b dose ranging study with some initial data expected in the H1 2019 and top-line dose ranging data in late 2019. A pediatric Phase 3 study design has also been approved by the EMA. BPS-804 has orphan designation in the US and EU and has been accepted into the PRIME and Adaptive Pathways in EU;

  • MPH-966 for alpha-1 antitrypsin deficiency (AATD). The Company recently announced first patient in a Phase 2 dose ranging study in the US with data expected in late 2019;

  • BCT-197 for acute exacerbations of COPD (AECOPD). The Company announced positive top-line Phase 2 data in December 2017; and

  • BGS-649 for hypogonadotropic hypogonadism (HH). The Company announced positive top-line Phase 2b data in March 2018.

  • As at September 30, 2018 Mereo had (unaudited) total cash resources of approximately US$44.6 million 

FOR FURTHER ENQUIRIES:

Mereo BioPharma Group plc
+44 (0)333 023 7319
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer

Nominated Adviser and Joint Broker
Cantor Fitzgerald Europe

+44 (0)20 7894 7000
Phil Davies
Will Goode

Joint Broker
RBC Capital Markets

+44 (0)20 7653 4000
Rupert Walford
Jamil Miah

UK Public Relations Advisor to Mereo BioPharma
FTI Consulting

+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard

US Public Relations Advisor to Mereo BioPharma
Burns McClellan

+01 (0) 212 213 0006
Lisa Burns